Directories

Directories

AMS puts a “Physician in your pocket” with a digital library of clinically reviewed treatments or pharmaceuticals. Find and compare costs, treatment details, and risk analyses by using these searchable applications.

Orenitram for Pulmonary Arterial Hypertension

Orenitram for Pulmonary Arterial Hypertension

  United Therapeutics announced that the FDA has approved Orenitram (treprostinil) extended-release tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. RELATED: Cardiovascular Disease Resource Center The approval was based on data from FREEDOM-M, the primary efficacy study that included patients with WHO functional class II to III symptoms and etiologies of idiopathic of idiopathic or heritable PAH or PAH associated with connective tissue disease. Results showed that patients receiving Orenitram improved their median…

Read More Read More

Tretten Approved for Genetic Clotting Disorder

Tretten Approved for Genetic Clotting Disorder

  The FDA has approved Tretten (coagulation factor XIII A-subunit [recombinant]; Novo Nordisk) for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency, a rare clotting disorder. Tretten is the first recombinant product approved for this indication. RELATED: Hematological Disorders Resource Center Tretten is a recombinant analog of the human Factor XIII A-subunit that is produced in yeast cells and then further purified. It is a sterile freeze-dried powder that is reconstituted for…

Read More Read More

Nexavar to treat type of thyroid cancer

Nexavar to treat type of thyroid cancer

originally posted on FDA.gov FDA approves Nexavar to treat type of thyroid cancer The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. Thyroid cancer is a cancerous growth of the thyroid gland, which is located in the neck. Differentiated thyroid cancer is the most common type of thyroid cancer. The National Cancer Institute estimates that 60,220 Americans will be diagnosed with thyroid cancer and 1,850 will die from…

Read More Read More

FDA approves Imbruvica for rare blood cancer

FDA approves Imbruvica for rare blood cancer

originally posted on FDA.gov FDA approves Imbruvica for rare blood cancer Second drug with breakthrough therapy designation to receive FDA approval   The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. MCL is a rare form of non-Hodgkin lymphoma and represents about 6 percent of all non-Hodgkin lymphoma cases in the United States. By the time MCL is diagnosed, it usually has already…

Read More Read More

Johnson & Johnson false drug marketing

Johnson & Johnson false drug marketing

Johnson & Johnson will pay $2.2 billion to settle charges that the company marketed drugs for unapproved uses and paid “kickbacks” to doctors and nursing homes.     Originally published by CNNMoney, Nov 4th The penalties announced Monday involve fines and forfeiture to the federal government and several states. The settlement involves the schizophrenia drugs Risperdal and Invega, and the heart failure drug Natrecor, the company and Attorney General Eric Holder said. Johnson & Johnson and two subsidiaries “lined their…

Read More Read More

Johnson & Johnson false drug marketing

Johnson & Johnson false drug marketing

Johnson & Johnson will pay $2.2 billion to settle charges that the company marketed drugs for unapproved uses and paid “kickbacks” to doctors and nursing homes.     Originally published by CNNMoney, Nov 4th The penalties announced Monday involve fines and forfeiture to the federal government and several states. The settlement involves the schizophrenia drugs Risperdal and Invega, and the heart failure drug Natrecor, the company and Attorney General Eric Holder said. Johnson & Johnson and two subsidiaries “lined their…

Read More Read More

The Cost of Living

The Cost of Living

  New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars. Prompting some doctors to refuse to use them.   By Stephen S. Hall On August 3, 2012, the Food and Drug Administration approved a new cancer drug called Zaltrap as a safe and effective treatment for patients with advanced colon cancer. The approval was based on a large-scale clinical trial that showed that Zaltrap, given in combination with three previously approved drugs…

Read More Read More

Rising Healthcare Costs

Rising Healthcare Costs

Rising Healthcare Costs: A Deeper Look Into Catastrophic Claims Advanced Medical Strategies contributed the article below to the Self-Insurer Magazine It comes as no surprise to anyone that health care costs continue to rise. We are all aware of the common conditions that result in catastrophic claims: cancers, premature babies, spinal surgeries, end-stage renal disease, and diseases requiring transplants. The list is seemingly endless. This article’s focus is on overlooked conditions, their treatments and associated catastrophic claims costs (which often times…

Read More Read More

Diagnoses Database Alters the Industry

Diagnoses Database Alters the Industry

Massachusetts-Based Company Launches Healthcare Diagnoses Database That Alters the Landscape for Insurance Industry; Predicts Costs and Risks for Reinsurers   Lynnfield, MA [date] –The Affordable Care Act has dramatically increased the number of businesses who self-insure, creating a greater need for companies who provide stop-loss or reinsurance policies to look deeper into their long-term liabilities. For those types of insurance providers, catastrophic diagnoses represent risks that must be carefully understood and managed.  Until now, when informed about a serious or…

Read More Read More